Overview

Acute Neurological ICU Sedation Trial (ANIST)

Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
Dexmedetomidine (Precedex, Hospira) is a "super" selective alpha2-agonist - 8-10x more avid binding to alpha2 receptors than clonidine - and may have particularly favorable characteristics as a continuous i.v. infusion sedative for critically ill neuroscience patients. Its combination of anxiolysis, analgesia, without undue lethargy may make it an ideal agent where frequent neurological examinations are important. Unclear, however, is whether Precedex is superior to current common i.v. sedation protocols, and if there are any undue concerns of this agent on cerebral physiology and cortical stimulation.
Phase:
Phase 2
Details
Lead Sponsor:
Daniel Hanley
Johns Hopkins University
Treatments:
Dexmedetomidine
Fentanyl
Propofol